次世代抗体治療薬の世界市場に関する洞察と2028年までの予測Global Next Generation Antibody Therapeutics Market Insights and Forecast to 2028 市場の分析と洞察。次世代抗体治療薬の世界市場 COVID-19のパンデミックとスペイン・ウクライナ戦争の影響により、2022年に1億2257.15万米ドルと推定される次世代抗体治療薬の世界市場は、2028年までに3億9424.4... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー市場の分析と洞察。次世代抗体治療薬の世界市場COVID-19のパンデミックとスペイン・ウクライナ戦争の影響により、2022年に1億2257.15万米ドルと推定される次世代抗体治療薬の世界市場は、2028年までに3億9424.45万米ドルの修正規模に達すると予測され、予測期間2022~2028年に年率21.51%で成長するとされています。 次世代抗体治療薬のアメリカ市場は、2022年の7億3624万米ドルから、2022年から2028年の予測期間中にCAGR18.38%で増加し、2028年には2億25678万米ドルに達すると予測されます。 次世代抗体治療薬のヨーロッパ市場は、2022年の2億2,840万米ドルから、2022年から2028年の予測期間中にCAGR25.72%で増加し、2028年には9億1,950万米ドルに達すると予測されます。 次世代抗体治療薬の日本市場は、2022年の1億1542万米ドルから2028年には3億3761万米ドルに増加し、予測期間中にCAGR19.36%で到達すると予測されます。 次世代抗体治療薬の世界的な主要企業には、ロシュ、アムジェン、武田薬品、ファイザー、シーゲン社、ADCセラピューティックSA、アステラス、第一三共、イミュノミクス(ギリアド)などが含まれます。2021年、世界の上位5社の売上高シェアは約88.78%でした。 レポートの内容 本レポートでは、次世代抗体治療薬の世界市場規模を概観しています。2017年~2021年の歴史的な市場収益データ、2022年の予測、2028年までのCAGRの予測により、世界市場の動向を分析します。 次世代抗体治療薬の主要生産者を調査し、主要地域と国の収益も提供します。次世代抗体治療薬の今後の市場可能性のハイライトと、この市場を様々なセグメントとサブセグメントに分けて予測するための主要地域/国に焦点を当てます。米国、カナダ、メキシコ、ブラジル、日本、中国、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国々の国別データおよび市場価値分析。 本レポートでは、2017年から2022年までのデータをもとに、次世代抗体治療薬の収益、主要企業の市場シェア、業界ランキングに焦点を当てます。世界の次世代抗体治療薬市場における主要なステークホルダーを特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別収益に基づき分析します。本レポートは、ステークホルダーが競争環境を理解し、より多くの洞察を得て、ビジネスや市場戦略をより良い方法で位置づけるのに役立ちます。 本レポートでは、2017年から2028年までのタイプ別、アプリケーション別のセグメントデータ、収益、成長率などを分析しています。次世代抗体治療薬の収益、予測成長動向、生産技術、アプリケーション、エンドユーザー産業の市場規模を評価・予測。 ロシュ、アムジェン、武田薬品、ファイザー、セーゲン社、ADCセラピューティックSA、アステラス、第一三共、イムノメディックス(ギリアド)など、世界の主要企業の説明的な企業プロフィール。 会社別 ロシュ アムジェン ファイザー 武田薬品工業 第一三共 セーゲン アステラス製薬 イムノメディックス GSK イムノコア ADCセラピューティック タイプ別セグメント 抗体薬物複合体(ADC) 二重特異性抗体(BsAb) 用途別セグメント 癌 血友病 その他の非癌性疾患 地域別 北アメリカ 米国 カナダ メキシコ アジア・パシフィック 中国 日本 韓国 インド 東南アジア その他のアジア 欧州 ドイツ フランス 英国 イタリア スペイン その他の欧州 南米 ブラジル アルゼンチン 南米のその他 中近東・アフリカ 中東 アフリカ 各章の概要 第1章:レポートスコープ、市場セグメント(製品タイプ、アプリケーションなど)別の市場規模、将来の発展可能性などのエグゼクティブサマリーを紹介します。市場の現状と短期、中期、長期の展開の可能性を高次元で把握することができます。 第2章 次世代抗体治療薬の世界レベルおよび地域レベルでの収益各地域とその主要国の市場規模や発展可能性を定量的に分析し、世界各国の市場発展や今後の発展展望、市場スペース、生産能力などを紹介しています。また、市場のダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界各社が直面する課題とリスク、業界の関連政策の分析についても紹介しています。 第3章:次世代抗体治療薬企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、M&A情報などを詳細に分析。 第4章:読者が異なる市場セグメントでブルーオーシャン市場を見つけることができるように、タイプ別の様々な市場セグメントの分析、収益、各市場セグメントの開発ポテンシャルをカバーする情報を提供します。 第5章:読者が異なる下流市場のブルーオーシャン市場を見つけるのを助けるために、アプリケーション別の様々な市場セグメントの分析、各市場セグメントの収益、および開発ポテンシャルをカバーすることを提供します。 第6章:北米のタイプ別、アプリケーション別、国別、各セグメントごとの収益。 第7章:ヨーロッパ:タイプ別、アプリケーション別、国別、各セグメントごとの収益。 第8章:アジア太平洋地域:タイプ別、アプリケーション別、地域別、セグメント別売上。 第9章:南米:タイプ別、アプリケーション別、国別、各セグメントごとの収益。 第10章:中東・アフリカ:タイプ別、アプリケーション別、国別、セグメント別売上。 第11章:主要企業のプロフィールを提供し、製品の説明や仕様、次世代抗体治療薬の収益、総利益、最近の開発など、市場の主要企業の基本状況を詳細に紹介します。 第12章 アナリストの視点/結論 目次1 Report Overview 11.1 Study Scope 1 1.2 Market Analysis by Type 1 1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1 1.2.2 Antibody Drug Conjugate (ADC) 3 1.2.3 Bispecific Antibody (BsAb) 3 1.3 Market by Application 4 1.3.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 5 1.3.2 Cancer 6 1.3.3 Haemophilia 7 1.3.4 Other Non-Cancer Diseases 8 1.4 Study Objectives 9 1.5 Years Considered 10 2 Global Growth Trends 11 2.1 Global Next Generation Antibody Therapeutics Market Perspective (2017-2028) 11 2.2 Next Generation Antibody Therapeutics Growth Trends by Region 12 2.2.1 Next Generation Antibody Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 12 2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2017-2022) 13 2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2023-2028) 14 2.3 Next Generation Antibody Therapeutics Market Dynamics 15 2.3.1 Next Generation Antibody Therapeutics Industry Trends 15 2.3.2 Next Generation Antibody Therapeutics Market Drivers 15 2.3.3 Next Generation Antibody Therapeutics Market Challenges and Restraints 16 3 Competition Landscape by Key Players 17 3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue 17 3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2017-2022) 17 3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2017-2022) 18 3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 19 3.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue 21 3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio 22 3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI) 22 3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2021 23 3.5 Next Generation Antibody Therapeutics Key Players Head office and Area Served 23 3.6 Key Players Next Generation Antibody Therapeutics Product Solution and Service 24 3.7 Date of Enter into Next Generation Antibody Therapeutics Market 24 3.8 Mergers & Acquisitions, Expansion Plans 25 4 Next Generation Antibody Therapeutics Breakdown Data by Type 26 4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2017-2022) 26 4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2023-2028) 27 5 Next Generation Antibody Therapeutics Breakdown Data by Application 28 5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2017-2022) 28 5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2023-2028) 29 6 North America 30 6.1 North America Next Generation Antibody Therapeutics Market Size (2017-2028) 30 6.2 North America Next Generation Antibody Therapeutics Market Size by Type 30 6.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 30 6.2.2 North America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 31 6.2.3 North America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 31 6.3 North America Next Generation Antibody Therapeutics Market Size by Application 32 6.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 32 6.3.2 North America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 32 6.3.3 North America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 33 6.4 North America Next Generation Antibody Therapeutics Market Size by Country 33 6.4.1 North America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 33 6.4.2 North America Next Generation Antibody Therapeutics Market Share by Country (2023-2028) 34 6.4.3 United States 35 6.4.4 Canada 35 6.4.5 Mexico 36 7 Europe 37 7.1 Europe Next Generation Antibody Therapeutics Market Size (2017-2028) 37 7.2 Europe Next Generation Antibody Therapeutics Market Size by Type 37 7.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 37 7.2.2 Europe Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 38 7.2.3 Europe Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 38 7.3 Europe Next Generation Antibody Therapeutics Market Size by Application 39 7.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 39 7.3.2 Europe Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 39 7.3.3 Europe Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 40 7.4 Europe Next Generation Antibody Therapeutics Market Size by Country 40 7.4.1 Europe Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 40 7.4.2 Europe Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 41 7.4.3 Germany 42 7.4.4 France 42 7.4.5 U.K. 43 7.4.6 Italy 43 7.4.7 Spain 44 8 Asia-Pacific 45 8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2017-2028) 45 8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type 45 8.2.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 45 8.2.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 46 8.2.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 46 8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application 47 8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 47 8.3.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 47 8.3.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 48 8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region 48 8.4.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2017-2022) 48 8.4.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2023-2028) 49 8.4.3 China 50 8.4.4 Japan 50 8.4.5 South Korea 51 8.4.6 Southeast Asia 51 8.4.7 India 52 9 South America 53 9.1 South America Next Generation Antibody Therapeutics Market Size (2017-2028) 53 9.2 South America Next Generation Antibody Therapeutics Market Size by Type 53 9.2.1 South America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 53 9.2.2 South America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 54 9.2.3 South America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 54 9.3 South America Next Generation Antibody Therapeutics Market Size by Application 55 9.3.1 South America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 55 9.3.2 South America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 55 9.3.3 South America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 56 9.4 South America Next Generation Antibody Therapeutics Market Size by Country 56 9.4.1 South America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 56 9.4.2 South America Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 57 9.4.3 Brazil 58 9.4.4 Argentina 58 10 Middle East & Africa 59 10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2017-2028) 59 10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type 59 10.2.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 59 10.2.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 60 10.2.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 60 10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application 61 10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 61 10.3.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 61 10.3.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 62 10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country 62 10.4.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 62 10.4.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 63 10.4.3 Middle East 64 10.4.4 Africa 64 11 Key Players Profiles 65 11.1 Roche 65 11.1.1 Roche Company Details 65 11.1.2 Roche Business Overview 65 11.1.3 Roche Next Generation Antibody Therapeutics Introduction 66 11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 69 11.1.5 Roche Recent Development 70 11.2 Amgen 70 11.2.1 Amgen Company Details 70 11.2.2 Amgen Business Overview 71 11.2.3 Amgen Next Generation Antibody Therapeutics Introduction 71 11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 72 11.2.5 Amgen Recent Development 73 11.3 Takeda 74 11.3.1 Takeda Company Details 74 11.3.2 Takeda Business Overview 74 11.3.3 Takeda Next Generation Antibody Therapeutics Introduction 74 11.3.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 76 11.3.5 Takeda Recent Development 77 11.4 Pfizer 78 11.4.1 Pfizer Company Details 78 11.4.2 Pfizer Business Overview 78 11.4.3 Pfizer Next Generation Antibody Therapeutics Introduction 79 11.4.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 80 11.4.5 Pfizer Recent Development 81 11.5 Seagen Inc. 81 11.5.1 Seagen Inc. Company Details 81 11.5.2 Seagen Inc. Business Overview 82 11.5.3 Seagen Inc. Next Generation Antibody Therapeutics Introduction 82 11.5.4 Seagen Inc. Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 84 11.5.5 Seagen Inc. Recent Development 85 11.6 Astellas 85 11.6.1 Astellas Company Details 85 11.6.2 Astellas Business Overview 86 11.6.3 Astellas Next Generation Antibody Therapeutics Introduction 86 11.6.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 87 11.6.5 Astellas Recent Development 87 11.7 Daiichi Sankyo 88 11.7.1 Daiichi Sankyo Company Details 88 11.7.2 Daiichi Sankyo Business Overview 88 11.7.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction 89 11.7.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 91 11.7.5 Daiichi Sankyo Recent Development 91 11.8 Immunomedics (Gilead) 92 11.8.1 Immunomedics (Gilead) Company Details 92 11.8.2 Immunomedics (Gilead) Business Overview 92 11.8.3 Immunomedics (Gilead) Next Generation Antibody Therapeutics Introduction 93 11.8.4 Immunomedics (Gilead) Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 93 11.8.5 Immunomedics (Gilead) Recent Development 94 11.9 GSK 94 11.9.1 GSK Company Details 94 11.9.2 GSK Business Overview 95 11.9.3 GSK Next Generation Antibody Therapeutics Introduction 95 11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 96 11.9.5 GSK Recent Development 96 11.10 Immunocore 97 11.10.1 Immunocore Company Details 97 11.10.2 Immunocore Business Overview 97 11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction 98 11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 98 11.10.5 Immunocore Recent Development 99 11.11 ADC Therapeutics SA 99 11.11.1 ADC Therapeutics SA Company Details 99 11.11.2 ADC Therapeutics SA Business Overview 100 11.11.3 ADC Therapeutics SA Next Generation Antibody Therapeutics Introduction 100 11.11.4 ADC Therapeutics SA Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 101 11.11.5 ADC Therapeutics SA Recent Development 102 12 Analyst's Viewpoints/Conclusions 103 13 Appendix 104 13.1 Research Methodology 104 13.1.1 Methodology/Research Approach 104 13.1.2 Data Source 107 13.2 Disclaimer 110 13.3 Author Details 110
SummaryMarket Analysis and Insights: Global Next Generation Antibody Therapeutics Market Table of Contents1 Report Overview 11.1 Study Scope 1 1.2 Market Analysis by Type 1 1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1 1.2.2 Antibody Drug Conjugate (ADC) 3 1.2.3 Bispecific Antibody (BsAb) 3 1.3 Market by Application 4 1.3.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 5 1.3.2 Cancer 6 1.3.3 Haemophilia 7 1.3.4 Other Non-Cancer Diseases 8 1.4 Study Objectives 9 1.5 Years Considered 10 2 Global Growth Trends 11 2.1 Global Next Generation Antibody Therapeutics Market Perspective (2017-2028) 11 2.2 Next Generation Antibody Therapeutics Growth Trends by Region 12 2.2.1 Next Generation Antibody Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 12 2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2017-2022) 13 2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2023-2028) 14 2.3 Next Generation Antibody Therapeutics Market Dynamics 15 2.3.1 Next Generation Antibody Therapeutics Industry Trends 15 2.3.2 Next Generation Antibody Therapeutics Market Drivers 15 2.3.3 Next Generation Antibody Therapeutics Market Challenges and Restraints 16 3 Competition Landscape by Key Players 17 3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue 17 3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2017-2022) 17 3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2017-2022) 18 3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 19 3.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue 21 3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio 22 3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI) 22 3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2021 23 3.5 Next Generation Antibody Therapeutics Key Players Head office and Area Served 23 3.6 Key Players Next Generation Antibody Therapeutics Product Solution and Service 24 3.7 Date of Enter into Next Generation Antibody Therapeutics Market 24 3.8 Mergers & Acquisitions, Expansion Plans 25 4 Next Generation Antibody Therapeutics Breakdown Data by Type 26 4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2017-2022) 26 4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2023-2028) 27 5 Next Generation Antibody Therapeutics Breakdown Data by Application 28 5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2017-2022) 28 5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2023-2028) 29 6 North America 30 6.1 North America Next Generation Antibody Therapeutics Market Size (2017-2028) 30 6.2 North America Next Generation Antibody Therapeutics Market Size by Type 30 6.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 30 6.2.2 North America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 31 6.2.3 North America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 31 6.3 North America Next Generation Antibody Therapeutics Market Size by Application 32 6.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 32 6.3.2 North America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 32 6.3.3 North America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 33 6.4 North America Next Generation Antibody Therapeutics Market Size by Country 33 6.4.1 North America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 33 6.4.2 North America Next Generation Antibody Therapeutics Market Share by Country (2023-2028) 34 6.4.3 United States 35 6.4.4 Canada 35 6.4.5 Mexico 36 7 Europe 37 7.1 Europe Next Generation Antibody Therapeutics Market Size (2017-2028) 37 7.2 Europe Next Generation Antibody Therapeutics Market Size by Type 37 7.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 37 7.2.2 Europe Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 38 7.2.3 Europe Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 38 7.3 Europe Next Generation Antibody Therapeutics Market Size by Application 39 7.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 39 7.3.2 Europe Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 39 7.3.3 Europe Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 40 7.4 Europe Next Generation Antibody Therapeutics Market Size by Country 40 7.4.1 Europe Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 40 7.4.2 Europe Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 41 7.4.3 Germany 42 7.4.4 France 42 7.4.5 U.K. 43 7.4.6 Italy 43 7.4.7 Spain 44 8 Asia-Pacific 45 8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2017-2028) 45 8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type 45 8.2.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 45 8.2.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 46 8.2.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 46 8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application 47 8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 47 8.3.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 47 8.3.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 48 8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region 48 8.4.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2017-2022) 48 8.4.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2023-2028) 49 8.4.3 China 50 8.4.4 Japan 50 8.4.5 South Korea 51 8.4.6 Southeast Asia 51 8.4.7 India 52 9 South America 53 9.1 South America Next Generation Antibody Therapeutics Market Size (2017-2028) 53 9.2 South America Next Generation Antibody Therapeutics Market Size by Type 53 9.2.1 South America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 53 9.2.2 South America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 54 9.2.3 South America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 54 9.3 South America Next Generation Antibody Therapeutics Market Size by Application 55 9.3.1 South America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 55 9.3.2 South America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 55 9.3.3 South America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 56 9.4 South America Next Generation Antibody Therapeutics Market Size by Country 56 9.4.1 South America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 56 9.4.2 South America Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 57 9.4.3 Brazil 58 9.4.4 Argentina 58 10 Middle East & Africa 59 10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2017-2028) 59 10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type 59 10.2.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 59 10.2.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 60 10.2.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 60 10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application 61 10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 61 10.3.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 61 10.3.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 62 10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country 62 10.4.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 62 10.4.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 63 10.4.3 Middle East 64 10.4.4 Africa 64 11 Key Players Profiles 65 11.1 Roche 65 11.1.1 Roche Company Details 65 11.1.2 Roche Business Overview 65 11.1.3 Roche Next Generation Antibody Therapeutics Introduction 66 11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 69 11.1.5 Roche Recent Development 70 11.2 Amgen 70 11.2.1 Amgen Company Details 70 11.2.2 Amgen Business Overview 71 11.2.3 Amgen Next Generation Antibody Therapeutics Introduction 71 11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 72 11.2.5 Amgen Recent Development 73 11.3 Takeda 74 11.3.1 Takeda Company Details 74 11.3.2 Takeda Business Overview 74 11.3.3 Takeda Next Generation Antibody Therapeutics Introduction 74 11.3.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 76 11.3.5 Takeda Recent Development 77 11.4 Pfizer 78 11.4.1 Pfizer Company Details 78 11.4.2 Pfizer Business Overview 78 11.4.3 Pfizer Next Generation Antibody Therapeutics Introduction 79 11.4.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 80 11.4.5 Pfizer Recent Development 81 11.5 Seagen Inc. 81 11.5.1 Seagen Inc. Company Details 81 11.5.2 Seagen Inc. Business Overview 82 11.5.3 Seagen Inc. Next Generation Antibody Therapeutics Introduction 82 11.5.4 Seagen Inc. Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 84 11.5.5 Seagen Inc. Recent Development 85 11.6 Astellas 85 11.6.1 Astellas Company Details 85 11.6.2 Astellas Business Overview 86 11.6.3 Astellas Next Generation Antibody Therapeutics Introduction 86 11.6.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 87 11.6.5 Astellas Recent Development 87 11.7 Daiichi Sankyo 88 11.7.1 Daiichi Sankyo Company Details 88 11.7.2 Daiichi Sankyo Business Overview 88 11.7.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction 89 11.7.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 91 11.7.5 Daiichi Sankyo Recent Development 91 11.8 Immunomedics (Gilead) 92 11.8.1 Immunomedics (Gilead) Company Details 92 11.8.2 Immunomedics (Gilead) Business Overview 92 11.8.3 Immunomedics (Gilead) Next Generation Antibody Therapeutics Introduction 93 11.8.4 Immunomedics (Gilead) Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 93 11.8.5 Immunomedics (Gilead) Recent Development 94 11.9 GSK 94 11.9.1 GSK Company Details 94 11.9.2 GSK Business Overview 95 11.9.3 GSK Next Generation Antibody Therapeutics Introduction 95 11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 96 11.9.5 GSK Recent Development 96 11.10 Immunocore 97 11.10.1 Immunocore Company Details 97 11.10.2 Immunocore Business Overview 97 11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction 98 11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 98 11.10.5 Immunocore Recent Development 99 11.11 ADC Therapeutics SA 99 11.11.1 ADC Therapeutics SA Company Details 99 11.11.2 ADC Therapeutics SA Business Overview 100 11.11.3 ADC Therapeutics SA Next Generation Antibody Therapeutics Introduction 100 11.11.4 ADC Therapeutics SA Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 101 11.11.5 ADC Therapeutics SA Recent Development 102 12 Analyst's Viewpoints/Conclusions 103 13 Appendix 104 13.1 Research Methodology 104 13.1.1 Methodology/Research Approach 104 13.1.2 Data Source 107 13.2 Disclaimer 110 13.3 Author Details 110
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(抗生物薬)の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(antibody)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |